ZEVASKYN Launch Gains Traction: Q2 Revenue Up 31% to $11.4M, CMS NTAP Secured
ABEO sits 67% above its 52-week low of $4.
Summary
Abeona reported Q2 2026 ZEVASKYN revenue of $11.4 million, up 31% sequentially from $8.7 million, with five patients treated in the quarter and three more in Q3 to-date. The company secured CMS NTAP status effective October 1, 2026, which should improve hospital reimbursement for Medicare patients (about 10% of RDEB cases). Cash stands at $146.8 million, down from $191.4 million at year-end, while net loss widened to $20.2 million from $17.1 million in Q1, missing analyst expectations. The QTC network expanded to seven sites with activations at NewYork-Presbyterian/Columbia, CHOP, and Cincinnati Children's.
At the time of this announcement, ABEO was trading at $6.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $425.2M. The 52-week trading range was $4.00 to $7.65. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.